Humacyte sets price for 28.4 million shares at $2.11 in direct registered offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Securities Purchase Agreement: Humacyte has entered into a securities purchase agreement with institutional investors to sell approximately $60 million worth of common stock and warrants in an oversubscribed registered direct offering.
Details of the Offering: The agreement includes the sale of 28,436,018 shares and warrants, with an exercise price of $2.11 per share, expected to close around October 8, 2025, pending customary closing conditions.
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.88 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.020
Low
3.00
Averages
5.88
High
11.00
Current: 1.020
Low
3.00
Averages
5.88
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
